P/E at 35.02 vs Industry's 37.44: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount to Industry Average

The current P/E of 35.02 for Sun Pharmaceutical Industries Ltd represents a modest discount of approximately 6.5% relative to the sector average of 37.44. This suggests that the market is pricing the stock with a slightly more conservative outlook compared to its peers. Given the company’s large-cap status with a market capitalisation of ₹4,43,637.04 crores, this valuation level indicates a balance between growth expectations and risk considerations. The premium or discount to industry P/E often reflects investor sentiment on earnings visibility and sector cyclicality — Sun Pharma’s valuation suggests a cautious optimism rather than exuberance.

Performance Across Timeframes: Momentum Divergence

Examining the stock’s returns reveals a compelling divergence. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 13.36% gain, significantly outperforming the Sensex’s 8.97% loss during the same period. This outperformance extends to longer horizons as well, with three-year and five-year returns of 63.40% and 140.21% respectively, dwarfing the Sensex’s 13.22% and 24.80% gains. However, the short-term momentum tells a different story: the stock has declined by 1.01% over the last three months, though this is still better than the Sensex’s 1.92% drop. The one-month and one-week returns also show slight underperformance relative to the benchmark, with -2.73% and -0.24% respectively.

This pattern suggests that while the stock has demonstrated strong resilience and growth over longer periods, recent market conditions or company-specific factors have tempered near-term enthusiasm — is this a temporary pause or a sign of shifting fundamentals? The year-to-date return of 7.52% remains positive and well ahead of the Sensex’s -12.30%, reinforcing the stock’s relative strength despite short-term fluctuations.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock price currently sits above its 5-day and 200-day moving averages but remains below the 20-day, 50-day, and 100-day moving averages. This configuration indicates a recent short-term bounce within a broader consolidation or corrective phase. Being above the 200-day moving average is generally a positive long-term signal, suggesting the stock has not broken down into a bear market territory. However, the failure to clear the intermediate-term moving averages points to resistance and a lack of sustained upward momentum in the medium term.

The 5-day average support may reflect short-term buying interest, but the inability to surpass the 20-day and 50-day averages raises questions about the strength of this recovery — is this a genuine recovery or a relief rally that will fade at the 50 DMA? Investors often watch these moving averages closely as they can signal trend continuation or reversal.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 28 stocks having declared results so far. Of these, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution suggests a sector grappling with uneven earnings momentum, possibly due to regulatory pressures, pricing challenges, or global supply chain issues. Within this context, Sun Pharmaceutical Industries Ltd’s ability to maintain positive returns over the year and outperform the sector average P/E ratio is notable. However, the recent short-term softness aligns with the sector’s mixed signals, reflecting broader industry headwinds.

Rating Reassessment: Previously Rated Buy

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as a Buy, but the rating was updated on 03 Sep 2026. While the current rating is not disclosed, the reassessment coincides with the observed valuation-performance tension and the mixed technical signals. The stock’s Mojo Score stands at 67.0, indicating a moderate overall assessment. The rating update invites investors to consider the full spectrum of data — valuation, performance across timeframes, and technical indicators — before drawing conclusions about the stock’s near-term prospects. What is the current rating for Sun Pharmaceutical Industries Ltd given these factors?

Comparative Performance: Outperforming Sensex Over Most Horizons

Looking beyond the immediate, Sun Pharmaceutical Industries Ltd has delivered substantial alpha relative to the Sensex over multiple timeframes. The 3-year return of 63.40% and 5-year return of 140.21% far exceed the Sensex’s 13.22% and 24.80% respectively. Even the 10-year return of 137.02% is competitive, though slightly below the Sensex’s 160.69%. This long-term outperformance underscores the company’s ability to generate shareholder value over extended periods despite cyclical pressures. The recent short-term underperformance, however, signals caution and the need to monitor momentum closely — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Data-Driven View

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount to its sector, with strong long-term performance but recent short-term momentum challenges. The mixed moving average configuration suggests a tentative recovery within a broader consolidation phase. Sector results are mixed, reflecting industry-wide uncertainties. The rating reassessment from Buy to Hold by MarketsMOJO on 03 Sep 2026 aligns with these nuanced signals, emphasising the importance of weighing both valuation and technical factors carefully. What does the current rating imply for investors navigating this complex landscape?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today